RBCC: Global Scientific Community Embraces New Parkinson’s Therapy

Rainbow BioSciences, LLC, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), announced today that its current joint venture target, Amarantus BioSciences, Inc. (OTCBB: AMBS), has cited several new peer-reviewed articles detailing its new protein therapy MANF to its website, bringing the total to 20.

A listing of the citations can be viewed on the company’s website at www.amarantus.com/investor-relations/scientific-publications.html.

The publications cited on Amarantus’ website are proof that there is significant interest in this new therapy within the global scientific community. There have been no major breakthroughs in the treatment of Parkinson’s disease and other neurodegenerative disorders in a very long time, and the demand for effective new treatments for these afflictions is very high. Both RBCC and Amarantus look forward to the possibility of helping to bring MANF to a market hungry for a potential cure.

MANF is a pre-clinical natural therapeutic protein being developed for the treatment of disorders associated with endoplasmic reticulum stress in cells, including Parkinson’s, Traumatic Brain Injury (TBI), Alzheimer’s and more. The protein acts as a molecular chaperone that improves protein folding in cells’ endoplasmic reticulum via the Unfolded Protein Response (UPR).

Currently, Amarantus is focused on achieving the required protocols to gain regulatory approval to initiate human clinical studies of MANF.

RBCC announced earlier this week that the company signed a letter of intent to advance Amarantus’ Parkinson’s disease program. RBCC has initiated due diligence toward a potential definitive agreement with the company. If future clinical studies confirm MANF’s potential for treating Parkinson’s and other diseases, the product could prove extremely lucrative around the world.

For more information on Rainbow BioSciences, RBCC’s biotechnology division, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ: CTIC), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Elan Corp. (NYSE: ELN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.